Ascendis Pharma A/S (NASDAQ:ASND) Earns "Overweight" Rating from Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its "overweight" rating reaffirmed by Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports. They presently have a $173.00 price target on the biotechnology company's stock. Cantor Fitzgerald's target price would indicate a potential upside of 22.79% from the stock's previous close.

A number of other brokerages also recently issued reports on ASND. Jefferies Financial Group initiated coverage on Ascendis Pharma A/S in a research report on Wednesday, December 20th. They issued a "buy" rating and a $150.00 price target for the company. JPMorgan Chase & Co. increased their target price on Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an "overweight" rating in a research note on Tuesday, April 2nd. Citigroup increased their target price on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a "buy" rating in a research note on Thursday, February 8th. Wedbush raised their price target on Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an "outperform" rating in a research note on Thursday, February 8th. Finally, StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Monday, December 25th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $173.25.

Ascendis Pharma A/S Stock Down 0.9 %

ASND stock traded down $1.28 during midday trading on Thursday, hitting $140.89. The company's stock had a trading volume of 222,167 shares, compared to its average volume of 374,777. Ascendis Pharma A/S has a 12 month low of $66.03 and a 12 month high of $161.00. The firm has a market capitalization of $8.20 billion, a price-to-earnings ratio of -15.23 and a beta of 0.50. The company has a 50 day moving average of $149.20 and a two-hundred day moving average of $123.87.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, beating analysts' consensus estimates of ($2.15) by $0.49. The firm had revenue of $148.62 million during the quarter, compared to the consensus estimate of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. On average, analysts anticipate that Ascendis Pharma A/S will post -4.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC purchased a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at approximately $25,000. Private Ocean LLC acquired a new position in Ascendis Pharma A/S during the first quarter worth $36,000. US Bancorp DE boosted its stake in Ascendis Pharma A/S by 35.2% during the fourth quarter. US Bancorp DE now owns 284 shares of the biotechnology company's stock worth $36,000 after buying an additional 74 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock worth $40,000 after buying an additional 151 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock worth $42,000 after buying an additional 91 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.